Search Results - "Strutton, David R."

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data.

Authors: Strutton, David R. Farkouh, Raymond A. Rubin, Jaime L. et al.

Source: BMC Infectious Diseases. 2012, Vol. 12 Issue 1, p175-178. 4p. 2 Charts.

Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions.

Authors: Weycker, Derek Farkouh, Raymond A. Strutton, David R. et al.

Source: BMC Health Services Research. 5/13/2016, Vol. 16, p1-10. 10p. 3 Charts, 3 Graphs.

Rates of pneumonia among children and adults with chronic medical conditions in Germany.

Authors: Pelton, Stephen I. Shea, Kimberly M. Farkouh, Raymond A. et al.

Source: BMC Infectious Diseases. 10/30/2015, Vol. 15, p1-8. 8p. 2 Charts, 2 Graphs.

Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.

Authors: Kohli, Michele A. Farkouh, Raymond A. Maschio, Michael J. et al.

Source: Health Affairs. Jul2015, Vol. 34 Issue 7, p1234-1240. 7p.

Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States.

Authors: McGarry, Lisa J. Gilmore, Kristen E. Rubin, Jaime L. et al.

Source: BMC Infectious Diseases. 2013, Vol. 13 Issue 1, p1-11. 11p. 3 Charts, 1 Graph.

Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic.

Authors: Rubin, Jaime L McGarry, Lisa J. Klugman, Keith P. et al.

Source: BMC Infectious Diseases. 2010, Vol. 10 Issue 1, Special section p1-11. 11p. 1 Diagram, 3 Charts.